![[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir](https://www.eatg.org/wp-content/uploads/2023/11/f5b02e4d-add5-45fb-bdb0-4a48d0ea77af-900x500.jpg)
Bullish
Gilead Sciences announced that the FDA has granted priority review to its New Drug Application for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN), an i...
Neutral
Gilead Sciences CEO Daniel Patrick O'Day sold 10,000 shares of company stock for $1,291,600 on April 28th, reducing his ownership by 1.56%. This trans...
Bearish
Daniel O'Day, Chairman & CEO of Gilead Sciences Inc (GILD), sold 10,000 shares of the company on April 28, 2026, bringing his total holdings to 632,56...
Neutral
M&T Bank Corp significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by selling 147,548 shares in the fourth quarter, leaving them wit...
Gilead Sciences Inc. (GILD) saw its stock price increase by 0.94% today, breaking a six-day losing streak that resulted in a 3.32% decline over the pa...
Neutral
Gilead Sciences (NASDAQ: GILD) has announced the attainment of all regulatory approvals for its acquisition of Arcellx and has extended the tender off...
Bullish
Concurrent Investment Advisors LLC increased its holdings in Gilead Sciences by 30.4% in Q4 2025, bringing its total to 72,108 shares valued at approx...
Neutral
Axecap Investments LLC substantially reduced its stake in Gilead Sciences, Inc. during the fourth quarter, selling 37% of its shares but still holding...
Neutral
Calamos Advisors LLC reduced its stake in Gilead Sciences, Inc. by 3.9% in the fourth quarter, selling 9,121 shares and holding 225,569 shares valued ...
Neutral
China Universal Asset Management Co. Ltd. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.2% during the 4th quarter...
Neutral
GF Fund Management CO. LTD. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.9% in the 4th quarter, according to ...
Neutral
Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of GILD stock for $422,880 on April 15th, reducing his stake by 1.67%. The sale occurred under ...
Neutral
Johanna Mercier, Chief Comm & Corp Aff Officer at Gilead Sciences, sold 3,000 shares of common stock for $422,880 on April 15, 2026, under a Rule 10b5...
Neutral
Andrew D. Dickinson, CFO of Gilead Sciences, sold 3,000 shares of company stock for a total of $422,880 on April 15, 2026. This transaction was execut...
Neutral
Gilead Sciences (NASDAQ:GILD) is scheduled to release its Q1 2026 earnings on Thursday, April 23rd, with analysts expecting $2.10 EPS and revenue of $...
Bullish
Gilead Sciences Inc. (GILD) and Tempus AI (TEM) have expanded their multi-year oncology research and development collaboration. This agreement grants ...
Neutral
Tempus AI has expanded its collaboration with Gilead Sciences, granting Gilead enterprise-wide access to its AI-driven Lens platform and oncology data...